Researchers from Analysis Group, a global leader in health economics and outcomes research (HEOR), have co-developed a new framework that leverages findings from clinical trials and real-world ...
Shares of AbbVie Inc. ABBV rose 1.79% to $200.88 Thursday, on what proved to be an all-around poor trading session for the ...
Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...
AI startup OpenEvidence is raising a fresh round of capital from Sequoia to scale its chatbot for doctors. The new $75 ...
The rise of remote work is transforming real estate, driving demand for flexible workspaces, data centers, and suburban ...
AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...
Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...
Full Year 2024 Results Key Financial Results Revenue: US$56.3b (up 3.7% from FY 2023). Net ...
Driven by rising demand and investment in technological innovation, the tech industry's future looks promising. In this ...
Tokyo, Japan and Cambridge, UK, 14 February 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) provides an update on operational activities and reports its consolidated results for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback